Cholinergic interactions between donepezil and prucalopride in human colon: Potential to treat severe intestinal dysmotility

British Journal of Pharmacology

Volumn 170, Issue 6, 2013, Pages 1253-1261

  Broad, J ^a   Kung, V W S ^a   Boundouki, G ^a   Aziz, Q ^a   De Maeyer, J H ^b   Knowles, C H ^a   Sanger, G J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Movetis NV   (Belgium)

Author keywords

colon; donepezil; elderly; human; neostigmine; prucalopride; pseudo obstruction

Indexed keywords

DONEPEZIL; NEOSTIGMINE; PRUCALOPRIDE;

ADULT; AGED; AMPLITUDE MODULATION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ELECTRIC FIELD; ELECTROSTIMULATION; EVOKED RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; INTESTINAL DYSMOTILITY; INTESTINE MOTILITY; MALE; MUSCLE CONTRACTION; MUSCLE TONE; PRIORITY JOURNAL; TISSUE CHARACTERIZATION;

COLON; DONEPEZIL; ELDERLY; HUMAN; NEOSTIGMINE; PRUCALOPRIDE; PSEUDO-OBSTRUCTION;

ADULT; AGED; AGED, 80 AND OVER; BENZOFURANS; CHOLINESTERASE INHIBITORS; COLON; DRUG SYNERGISM; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; INDANS; MALE; MIDDLE AGED; MUSCLE CONTRACTION; PIPERIDINES; SEROTONIN 5-HT4 RECEPTOR AGONISTS;

EID: 84886800214     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12397     Document Type: Article

References (49)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Amaro R, Rogers AI, (2000). Neostigmine infusion: new standard of care for acute colonic pseudo-obstruction? Am J Gastroenterol 95: 304-305.
3. Bharucha AE, Phillips SF, (1999). Megacolon: acute, toxic, and chronic. Curr Treat Options Gastroenterol 2: 517-523.
4. Bharucha AE, Low PA, Camilleri M, Burton D, Gehrking TL, Zinsmeister AR, (2008). Pilot study of pyridostigmine in constipated patients with autonomic neuropathy. Clin Auton Res 18: 194-202.
5. Bharucha AE, Low P, Camilleri M, Veil E, Burton D, Kudva Y, et al. (2013). A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut 62: 708-715.
6. Birks J, (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev (1): CD005593.
7. Broad J, Sanger GJ, (2013). The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. Br J Pharmacol 168: 1859-1867.
8. 4 receptor agonist prucalopride and the cholinesterase inhibitor donepezil as prokinetic agents in human isolated colon. Proc Br Pharmacol Soc. Available at: http://www.pA2online.org/ abstracts/Vol8Issue1abst071P.pdf (accessed 3/10/2013).
9. Broad J, Mukherjee S, Samadi M, Martin JE, Dukes GE, Sanger GJ, (2012). Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol 167: 763-774.
10. Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L, (2009). Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 21: 1256-e117.
11. 4 receptor agonist. Neurogastroenterol Motil 21: 1197-e108.
12. 4 receptor agonists enhance both cholinergic and nitrergic activity in human isolated colon circular muscle. Neurogastroenterol Motil 18: 853-861.
13. 4 receptor activation and acetylcholinesterase inhibition in human colon and rat forestomach. Neurogastroenterol Motil 20: 539-545.
14. Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R, (2012). Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 35: 587-599.
15. Coremans G, (2008). Prucalopride: the evidence for its use in the treatment of chronic constipation. Core Evid 3: 45-54.
16. Coulie B, Camilleri M, (1999). Intestinal pseudo-obstruction. Annu Rev Med 50: 37-55.
17. Doody RS, Ferris S, Salloway S, Yijun S, Goldman R, Yikang X, et al. (2010). Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. Am J Alzheimers Dis Other Demen 25: 155-159.
18. Ebert E, (2012). Gastrointestinal involvement in spinal cord injury: a clinical perspective. J Gastrointestin Liver Dis 21: 75-82.
19. Elsner JL, Smith JM, Ensor CR, (2012). Intravenous neostigmine for postoperative acute colonic pseudo-obstruction. Ann Pharmacother 46: 430-435.
20. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, et al. (2010). Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 32: 1234-1251.
21. Giorgio R, Knowles CH, (2009). Acute colonic pseudo-obstruction. Br J Surg 96: 229-239.
22. Hyatt R, (1987). Colonic pseudo-obstruction: an important complication in hospitalized elderly patients. Age Ageing 16: 145-152.
23. Imbimbo BP, (2001). Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 15: 375-390.
24. Jarvie EM, Cellek S, Sanger GJ, (2008). Potentiation by cholinesterase inhibitors of cholinergic activity in rat isolated stomach. Pharmacol Res 58: 297-301.
25. 4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillations. J Pharmacol Exp Ther 341: 681-691.
26. 4 receptor agonist, cisapride, on neuronally evoked responses in human bladder, urethra, and ileum. Auton Neurosci 176: 70-77.
27. Law N-M, Bjarucha AE, Undale AS, Zinsmeister AR, (2001). Cholinergic stimulation enhances colonic motor activity, transit and sensation in humans. Am J Physiol 281: G1228-G1237.
28. Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, et al. (2011). Two randomized trials of linaclotide for chronic constipation. N Engl J Med 365: 527-536.
29. Lockhart IA, Mitchell SA, Kelly S, (2009). Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. Dement Geriatr Cogn Disord 28: 389-403.
30. Loftus CG, Harewood GC, Baron TH, (2002). Assessment of predictors of response to neostigmine for acute colonic pseudo-obstruction. Am J Gastroenterol 97: 3118-3122.
31. McNamara R, Mihalakis MJ, (2008). Acute colonic pseudo-obstruction: rapid correction with neostigmine in the emergency department. J Emerg Med 35: 167-170.
32. Maselli MA, Trisolini P, Demma I, Pezzolla F, De Ponti F, (2011). Gender- and age-related differences in muscular and nerve-mediated responses in human colon. Dig Dis Sci 56: 352-358.
33. Mehta R, John A, Nair P, Raj VV, Mustafa CP, Suvarna D, et al. (2006). Factors predicting successful outcome following neostigmine therapy in acute colonic pseudo-obstruction: a prospective study. J Gastroenterol Hepatol 21: 459-461.
34. O'Dea CJ, Brookes JH, Wattchow DA, (2010). The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine. Colorectal Dis 12: 540-548.
35. Papa P, Turconi L, (2010). Neostigmine for the treatment of gastrointestinal atony: a report of one case. J Palliat Med 14: 1-4.
36. Ponec RJ, Saunders MD, Kimmey MB, (1999). Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med 341: 137-141.
37. Porter AJ, Wattchow DA, Brookes SJH, Costa M, (2002). Cholinergic and nitrergic interneurons in the myenteric plexus of the human colon. Gut 51: 70-75.
38. 4 receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br J Pharmacol 131: 927-932.
39. 4 receptors in the human isolated large intestinal circular muscle. Br J Pharmacol 129: 1601-1608.
40. Rogers SL, Friedhoff LT, (1998). Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 46: 1-6.
41. Rubiales AS, Hernansanz S, Gutierrez C, Del Valle ML, Flores LA, (2006). Neostigmine for refractory constipation in advanced cancer patients. J Pain Symptom Manage 32: 204-205.
42. 4 receptor pharmacology. Neurogastroenterol Motil 21: 1235-1238.
43. Sanger GJ, Broad J, Kung V, Knowles CH, (2013). Translational neuropharmacology: the use of human isolated gastrointestinal tissues. Br J Pharmacol 168: 28-43.
44. Saunders MD, (2007). Acute colonic pseudo-obstruction. Best Pract Res Clin Gastroenterol 21: 671-687.
45. Saunders MD, Kimmey MB, (2005). Systematic review: acute colonic pseudoobstruction. Aliment Pharmacol Ther 22: 917-925.
46. Singal AK, Rosman AS, Bauman WA, Korsten MA, (2006). Recent concepts in the management of bowel problems after spinal cord injury. Adv Med Sci 51: 15-22.
47. Tiseo PJ, Rogers SL, Friedhoff LT, (1998). Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 46: 13-18.
48. Trevisani GY, Hyman NH, Church JM, (2000). Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction. Dis Colon Rectum 43: 599-603.
49. Turégano-Fuentes F, Muňoz-Jiménez F, Del Valle-Hernández E, Perez-Diaz D, Calvo-Serrano M, De Tomás J, et al. (1997). Early resolution of Ogilvie's syndrome with intravenous neostigmine: a simple, effective treatment. Dis Colon Rectum 40: 1353-1357.